Financial toxicity and socioeconomic impact of cancer in Europe

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • OECI Working Group Health Economics - (Author)
  • J. Vancoppenolle - , Netherlands Cancer Institute, University of Twente (First author)
  • N. Franzen - , Netherlands Cancer Institute (Author)
  • L. Azarang - , Netherlands Cancer Institute (Author)
  • T. Juslin - , University of Helsinki (Author)
  • M. Krini - , Cyprus Association of Cancer Patients and Friends (PASYKAF) (Author)
  • T. Lubbers - , Maastricht University Medical Centre (UMC+), Maastricht University (Author)
  • J. Mattson - , University of Helsinki (Author)
  • D. Mayeur - , Centre Georges-François Leclerc (Author)
  • R. Menezes - , Netherlands Cancer Institute (Author)
  • J. Schmitt - , Center for Evidence-Based Healthcare (Author)
  • F. Scotte - , Institut Gustave Roussy (Author)
  • O. Seoane López - , Institut Català d'Oncologia - Hospital Duran i Reynals (Author)
  • T. Skaali - , University of Oslo (Author)
  • J. Ubels - , German Cancer Research Center (DKFZ) (Author)
  • M. Schlander - , German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • V. Retel - , Netherlands Cancer Institute, Erasmus University Rotterdam, Organisation of European Cancer Institutes (OECI) (Joint last author)
  • W. H. van Harten - , Netherlands Cancer Institute, University of Twente, Organisation of European Cancer Institutes (OECI) (Joint last author)

Abstract

Background: Even with universal health care, patients living with cancer often face substantial treatment-related costs and income loss in Europe. Insights into the socioeconomic impact of cancer within and across countries are needed to create awareness, inform policy, and develop targeted measurement instruments. The SEC study aims to explore the socioeconomic impact and financial toxicity of cancer and identify vulnerable patient groups across Europe. Patients and methods: To investigate experiences of a large number of patients, data were collected in a collaborative effort of hospitals and patient organizations across Europe through convenience sampling. Patients undergoing treatment currently or treated within the past 2 years could participate. A 44-item survey was developed to measure the socioeconomic impact following a cancer diagnosis. The primary outcome was the level of financial toxicity, measured by the Financial Index of Toxicity (FIT) score. To identify vulnerable groups, multiple regression analyses were used to investigate the association between the FIT score, clinical characteristics, and socioeconomic demographics, including cancer type, employment status, and country of residence. Results: A total of 2507 patients across Europe met the inclusion criteria. Fifty-six percent of the patients reported income loss and 86% additional treatment-related expenses. Sixteen percent of patients delayed or avoided medical visits, buying medication, surgery, or other health services. Next to a significant association of the country of residence, our regression models demonstrated that divorced, self-employed patients who were younger (-0.02; P = 0.000) and lower educated (0.75; P = 0.000) with a lower household income (1.21; P = 0.000) and children (0.21; P = 0.000) at the time of diagnosis reported significantly higher FIT scores compared with older patients who were married (-0.56; P = 0.000), retired (-1.55; P = 0.000), or employed (-0.56; P = 0.000). Conclusions: In every European Union country, a substantial number of patients with cancer report serious financial consequences and stress. Further research is critical to inform well-tailored policies and interventions to limit the socioeconomic impact on patients with cancer.

Details

Original languageEnglish
Article number105293
Number of pages11
JournalESMO open
Volume10
Issue number6
Early online dateJun 2025
Publication statusPublished - Jun 2025
Peer-reviewedYes

External IDs

PubMed 40494040
Scopus 105007539303

Keywords

Sustainable Development Goals

Keywords

  • Europe, financial toxicity, income loss, non-treatment adherence, oncology, socioeconomic impact